For Bone Cancer Patients, Limb-Sparing Surgery May Not Provide Better Quality Of Life Than Amputation

For Bone Cancer Patients, Limb-Sparing Surgery May Not Provide Better Quality Of Life Than Amputation
Limb-sparing surgery, which has been taking the place of amputation for bone and soft tissue sarcomas of the lower limb in recent years, may not provide much or even any additional benefit to patients according to a new review. The analysis, published in the September 15, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society, indicates that patients and physicians should rethink the pros and cons of limb-sparing surgery and amputation.

In Understanding Blood Clot Mechanics, Protein Unfolding Is Key

Fibrin, the chief ingredient of blood clots, is a remarkably versatile polymer. On one hand, it forms a network of fibers -- a blood clot -- that stems the loss of blood at an injury site while remaining pliable and flexible. On the other hand, fibrin provides a scaffold for thrombi, clots that block blood vessels and cause tissue damage, leading to myocardial infarction, ischemic stroke, and other cardiovascular diseases. More at...

New Therapeutic Option For Heartburn

New Therapeutic Option For Heartburn
Bayer Consumer Care New Zealand will launch the OTC Proton Pump Inhibitor (PPI) omeprazole in New Zealand under the Losec® brand in September. This follows the Medicine Classification Committee's recommended approval for the Rx to OTC switch of omeprazole 10 mg, which became effective by Gazette notice on 19 March 2009. Bayer New Zealand received an OTC license for omeprazole from AstraZeneca for the marketing of OTC omeprazole.